Skip to main content

Clinical trials help doctors find better ways to treat and prevent cancer. If you or a loved one has cancer, you might consider joining a clinical trial in order to try a new drug or treatment, or to help doctors develop better treatments for the future. Browse our list of current pancreatic clinical trials below, or search our clinical trials database by cancer type, drug, doctor, or protocol.

Prospective Pancreatic Tumor Repository

Trial Website: TBA
Status: Opening soon

This study is creating a biorepository of samples from a large group of patients with pancreatic tumors. Study participants will be asked for samples, including blood, urine, saliva, stool, and biopsy, although not all are required in order to participate. Creating this repository will allow future studies with IRB approval access to a large set of samples to analyze for advancements in diagnosis and treatment.

Key Inclusion:
• Patients at least 18 years old
• With any confirmed pancreatic tumor

Key Exclusion:
•  Patients unwilling or unable to contribute blood or tissue samples

Principal Investigator:
Jen Jen Yeh, MD
Study Coordinator:
Brent Henderson
(919) 966-7706

Comparing Two Methods to Follow Patients with Pancreatic Cysts

Trial Website: NCT04239573
Status: Opening soon at UNC

Pancreatic cysts are commonly discovered during CTs or MRIs performed for other reasons. The cysts will often be monitored to ensure they don’t change over the years. This multicenter study compares two different approaches for monitoring to see which leads to better outcomes. Participants will be randomized between either the high-intensity surveillance group with more frequent follow-up, or the low-intensity surveillance group. Both groups will be followed for 5 years.

Key Inclusion:
• Patients between the ages of 50 and 75
• Newly diagnosed pancreatic cyst greater than 1 cm on MRI or CT

Key Exclusion:
• Prior diagnosis of pancreatic cancer
• Chronic pancreatitis
• Family history of pancreatic cancer

Principal Investigator:
Jen Jen Yeh, MD
Study Coordinator:
Brent Henderson
(919) 966-7706

A Study of ERK Inhibition Alone or in Combination with HCQ in Patients with Pancreatic Cancer

Trial Website: NCT04386057
Status: Recruiting

This randomized phase II trial studies ERK inhibition to see how well it works when combined with the autophagy inhibitor, hydroxychloroquine, compared with ERK inhibition alone in patients with pancreatic cancer that has spread to other places in the body.

Key Inclusion:
• Patients at least 18 years old
• Patients must have biopsy proven and measurable pancreatic cancer
• Able to tolerate therapy

Key Exclusion:
• More than two lines of prior therapy
• History of allergic reactions to ERK inhibitors or hydroxychloroquine
• Concurrent uncontrolled illnesses

Principal Investigator:
Ashwin Somasundaram, MD
Study Coordinator:
Catherine Griffin
(984) 974-8771

Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Trial Website: NCT03375320
Status: Recruiting by invitation only

This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Key Inclusion:
• Patients must have biopsy proven neuroendocrine pancreatic tumors
• Patients must have measurable disease by CT or MRI scan
• Patients must have had at least one previous treatment with an FDA-approved line of therapy

Key Exclusion:
• Prior treatment with cabozantinib
• Concurrent uncontrolled illnesses

Principal Investigator:
Hanna Sanoff, MD
Study Coordinator:
Not listed

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Trial Website: NCT03454035
Status: Ongoing, but not recruiting

This phase I study is designed to establish the safety, maximally tolerated dose, and recommended phase II dose of the ERK inhibitor ulixertinib when combined with the CDK4/6 inhibitor palbociclib.

Key Inclusion:
• Patients at least 18 years old
• Patients must have biopsy proven and measurable pancreatic cancer
• Able to tolerate therapy

Key Exclusion:
• Cancer-directed treatment within the last 28 days
• Certain conflicting medicines
• Concurrent uncontrolled illnesses

Principal Investigator:
Hanna Sanoff, MD
Study Coordinator:
Not listed

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Trial Website: NCT03977233
Status: Recruiting

This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.

Key Inclusion:
• Patients at least 18 years old
• Patients must have proven and measurable pancreatic cancer
• Able to tolerate therapy

Key Exclusion:
• Evidence of metastatic pancreatic cancer
• Prior chemotherapy, chemoradiotherapy, or surgery for pancreatic cancer
• Any other malignancies in the past 5 years

Principal Investigator:
Ashwin Somasundaram, MD
Study Coordinator:
Catherine Griffin
(984) 974-8771

A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies

Trial Website: NCT03597581
Status: Recruiting

This is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01, which inhibits certain mechanisms of gastrointestinal cancer progression. RGX-202-01 will be studied as a single agent or in combination with FOLFIRI +/- bevacizumab. This study will fous on patients with advanced gastrointestinal tumors (i.e., locally advanced and unresectable, or metastatic) who have had PD on available standard systemic therapies or for which there are no standard systemic therapies of relevant clinical impact.

Key Inclusion:
• Patients at least 18 years old
• Patients must have proven and measurable pancreatic cancer
• Able to tolerate therapy

Key Exclusion:
• Additional malignancies that may confound results
• Ongoing adverse events from previous cancer treatments

Principal Investigator:
Hanna Sanoff, MD
Study Coordinator:
Not listed

Efficacy and Safety Study of Tisotumab Vedotin for Patients With
Solid Tumors

Trial Website: NCT03485209
Status: Recruiting

This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are three parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. In Part C, participants may receive tisotumab vedotin on Days 1 and 15 or Days 1, 8, and 15 on a 4- week cycle.

Key Inclusion:
• Relapsed, locally-advanced, or metastatic colorectal or pancreatic cancer patients who are not candidates for standard therapy
• Must have prior treatment and experienced disease progression

Key Exclusion:
• History of another malignancy within the last 3 years
• Certain uncontrolled medical conditions

Principal Investigator:
Shetal Patel, MD
Study Coordinator:
Not listed